AAV-mediated gene transfer for treatment of hemophilia, Curr Gene Ther, vol.5, pp.349-360, 2005. ,
Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges, Nature reviews Genetics, vol.12, pp.341-355, 2011. ,
Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection, Mol Ther, vol.16, pp.1073-1080, 2008. ,
Advances in recombinant adeno-associated viral vectors for gene delivery, Curr Gene Ther, vol.13, pp.335-345, 2013. ,
The complex and evolving story of T cell activation to AAV vector-encoded transgene products, Mol Ther, vol.19, pp.16-27, 2011. ,
Safety and efficacy of gene transfer for Leber's congenital amaurosis, N Engl J Med, vol.358, pp.2240-2248, 2008. ,
, , 2006.
, Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response, Nat Med, vol.12, pp.342-347
Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial, Gene therapy, vol.20, pp.361-369, 2013. ,
, , 2007.
, CD8(+) T-cell responses to adeno-associated virus capsid in humans, Nat Med, vol.13, pp.419-422
Progress and prospects: immune responses to viral vectors, Gene Ther, vol.17, pp.295-304, 2010. ,
Immune Responses to AAV in Clinical Trials, Curr Gene Ther, vol.11, pp.321-330, 2011. ,
Transient immunosuppression allows transgene expression following readministration of adenoassociated viral vectors, Hum Gene Ther, vol.9, pp.477-485, 1998. ,
Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX, Mol Ther, vol.1, pp.225-235, 2000. ,
Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products, Gene Ther, vol.14, pp.1249-1260, 2007. ,
Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgenespecific T cell responses, Hum Gene Ther, vol.20, pp.930-942, 2009. ,
Systemic protein delivery by muscle-gene transfer is limited by a local immune response, Blood, vol.105, pp.4226-4234, 2005. ,
Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials, Front Microbiol, vol.2, p.201, 2011. ,
Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy, Hum Gene Ther, vol.25, pp.180-188, 2014. ,
Major role of local immune responses in antibody formation to factor IX in AAV gene transfer, Gene Ther, vol.12, pp.1453-1464, 2005. ,
, , 2003.
, AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B, Blood, vol.101, pp.2963-2972
Immune Responses to AAV-Vectors, the Glybera Example from Bench to, Bedside. Front Immunol, vol.5, p.82, 2014. ,
Immune responses to AAV vectors: overcoming barriers to successful gene therapy, Blood, vol.122, pp.23-36, 2013. ,
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B, N Engl J Med, vol.365, pp.2357-2365, 2011. ,
Long-term safety and efficacy of factor IX gene therapy in hemophilia B, N Engl J Med, vol.371, pp.1994-2004, 2014. ,
A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism, J Exp Med, vol.204, pp.1757-1764, 2007. ,
Intestinal CD103+, but not CX3CR1+, antigen sampling cells migrate in lymph and serve classical dendritic cell functions, J Exp Med, vol.206, pp.3101-3114, 2009. ,
Oral tolerance, Immunol Rev, vol.241, pp.241-259, 2011. ,
A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis, Nature, vol.389, pp.737-742, 1997. ,
Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties, Immunology, vol.108, pp.481-492, 2003. ,
Plasmacytoid dendritic cells mediate oral tolerance, Immunity, vol.29, pp.464-475, 2008. ,
Peripheral deletion of antigen-reactive T cells in oral tolerance, Nature, vol.376, pp.177-180, 1995. ,
Induction of anergy or active suppression following oral tolerance is determined by antigen dosage, Proc Natl Acad Sci U S A, vol.91, pp.6688-6692, 1994. ,
Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration, J Immunol, vol.167, pp.4245-4253, 2001. ,
, , 2011.
, Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial, Lancet, vol.378, pp.319-327
Specific oral tolerance induction with raw hen's egg in children with very severe egg allergy: a randomized controlled trial, Pediatr Allergy Immunol, vol.24, pp.66-74, 2013. ,
Kinetic analysis of oral tolerance: memory lymphocytes are refractory to oral tolerance, J Immunol, vol.163, pp.3692-3698, 1999. ,
, , 2011.
, Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2, Muscle Gene Transfer. Front Microbiol, vol.2, p.199
, , 2012.
, Immunological tolerance to muscle autoantigens involves peripheral deletion of autoreactive CD8+ T cells, PloS one, vol.7, p.36444
Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer, Blood, vol.104, pp.969-977, 2004. ,
, , 2010.
, Extracellular NAD+ shapes the Foxp3+ regulatory T cell compartment through the ART2-P2X7 pathway, J Exp Med, vol.207, pp.2561-2568
Ecto-enzyme and signaling functions of lymphocyte CD73, Immunol Rev, vol.161, pp.95-109, 1998. ,
The molecular signature of CD8+ T cells undergoing deletional tolerance, Blood, vol.113, pp.4575-4585, 2009. ,
Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D, J Virol, vol.71, pp.7960-7962, 1997. ,
, , 2013.
, Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells, Nat Med, vol.19, pp.739-746
Interleukin-10-secreting Peyer's patch cells are responsible for active suppression in low-dose oral tolerance, Immunology, vol.103, pp.458-464, 2001. ,
Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells, Proc Natl Acad Sci U S A, vol.93, pp.388-391, 1996. ,
Oral tolerance correlates with high levels of lymphocyte activity, Cellular immunology, vol.280, pp.171-181, 2012. ,
Antigen-specific T cell activation and proliferation during oral tolerance induction, J Immunol, vol.162, pp.5868-5875, 1999. ,
Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice, Diabetes, vol.63, pp.2876-2887, 2014. ,
Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice, J Clin Invest, vol.122, pp.1717-1725, 2012. ,
Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis, Int Rev Immunol, vol.28, pp.465-486, 2009. ,
Mechanism of oral tolerance induction to therapeutic proteins, Adv Drug Deliv Rev, vol.65, pp.759-773, 2013. ,
Oral delivery of human biopharmaceuticals, autoantigens and vaccine antigens bioencapsulated in plant cells, Adv Drug Deliv Rev, vol.65, pp.782-799, 2013. ,
, , 2010.
, Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice, Proc Natl Acad Sci U S A, vol.107, pp.7101-7106